Transplant Genomics Kidney Transplant Test Gets Final Medicare Coverage Decision

Transplant Genomics said today that its TruGraf Blood Gene Expression kidney transplant test qualifies for Medicare coverage beginning on Nov. 25. TruGraf is a DNA microarray test that assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function, providing an alternative to surveillance biopsies. Earlier this year, Molecular Diagnostic Services Program administrator Palmetto GBA issued a draft local coverage determination for TruGraf, with a number of other Medicare Administrative Contractors following suit. According to Mansfield, Massachusetts-based Transplant Genomics — which was acquired by Eurofins Scientific in June — the Centers for Medicare and Medicaid Services has now released the final version of the coverage policy issued by Palmetto. --> READ MORE